Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
4147.TWO
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-0.19
vs -0.30
Q3.23
N/A
-0.02
vs -0.14
Q4.23
N/A
-0.24
vs -0.15
Q1.24
N/A
-0.06
vs -0.32
Q2.24
N/A
-0.10
vs -0.19
Q3.24
N/A
-0.14
vs -0.02
Q4.24
N/A
-0.44
vs -0.24
Q1.25
N/A
-0.09
vs -0.06
Q2.25
N/A
-0.13
vs -0.10
Q3.25
N/A
-0.24
vs -0.14
Sales Growth
YoY
Current
Estimates
Q2.23
+5%
104.2M vs 99.3M
Q3.23
+63%
157.6M vs 96.6M
Q4.23
-52%
158.2M vs 326.5M
Q1.24
+149%
178.9M vs 71.8M
Q2.24
+41%
146.9M vs 104.2M
Q3.24
-12%
138.5M vs 157.6M
Q4.24
-8%
145.8M vs 158.2M
Q1.25
-2%
176.2M vs 178.9M
Q2.25
+14%
167.7M vs 146.9M
Q3.25
+24%
171.7M vs 138.5M
Return on Equity
QoQ
Q2.23
-2%
-0.02
vs -0.03
Q3.23
0%
-0.00
vs -0.02
Q4.23
-2%
-0.02
vs -0.00
Q1.24
0%
-0.00
vs -0.02
Q2.24
-1%
-0.01
vs -0.00
Q3.24
-1%
-0.01
vs -0.01
Q4.24
-3%
-0.03
vs -0.01
Q1.25
-1%
-0.01
vs -0.03
Institutionnal Ownership
Relative Strength
4147.TWO
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes various drugs for the treatment and prevention of infectious diseases. The company develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.
TWO
Unprofitable
EPS improving
Unprofitable
EPS improving
-0.40Â ( -0.47%)
After-hours NaN$
0.00 (0.00%)
Relative Strenght
Volume Buzz
-7%
Earning Acce
No
Dist 52w H.
22%Quote Panel
Key Metrics
Forecast
297%2026-Revenue
-122%2026-EPS
-1101%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How 4147.TWO compares to sector?